Matrix Metalloproteinases in Cancer Biology

Matrix metalloproteinases (MMPs) comprise a family of zinc-dependent endopeptidases that orchestrate the remodelling of the extracellular matrix (ECM) through proteolytic degradation of collagens, proteoglycans and other structural proteins. Under physiological conditions, MMP activity is tightly controlled by tissue inhibitors of metalloproteinases (TIMPs), ensuring balanced ECM turnover during processes such as wound healing, embryogenesis and angiogenesis. In the context of cancer, dysregulated MMP expression and activity contribute to tumour initiation, local invasion, metastasis and the establishment of a supportive tumour microenvironment. Key roles include facilitating epithelial–mesenchymal transition, promoting vascular remodelling through release of pro-angiogenic factors and modulating immune cell infiltration. Aberrant MMP expression has been documented across diverse malignancies, with particular emphasis on gelatinases (MMP-2, MMP-9) in metastasis and stromal remodelling. Beyond their mechanistic importance, MMPs offer prognostic and diagnostic value as circulating biomarkers and therapeutic targets. However, early broad-spectrum MMP inhibitors were limited by dose-limiting toxicities, prompting renewed efforts to develop selective inhibitors, monoclonal antibodies and allosteric modulators. Advances in understanding MMP gene regulation, post-translational activation and crosstalk with growth factor signalling continue to reveal new opportunities for precision-based intervention in oncology.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Matrix Metalloproteinases in Cancer Biology publication trend

The graph below shows the total number of articles in matrix metalloproteinases in cancer biology across all publications each year (not limited to Nature Index journals).

Technical terms

Matrix metalloproteinase (MMP): A zinc-dependent protease that degrades components of the extracellular matrix.

Extracellular matrix (ECM): A complex network of proteins and polysaccharides that provides structural and biochemical support to cells.

Tissue inhibitor of metalloproteinases (TIMP): A family of endogenous proteins that bind to and inhibit MMP activity, regulating ECM turnover.

Epithelial–mesenchymal transition (EMT): A cellular programme by which epithelial cells acquire migratory and invasive mesenchymal characteristics.

Angiogenesis: The formation of new blood vessels from existing vasculature, critical for tumour growth and metastasis.

Metastasis: The process by which cancer cells spread from the primary tumour to establish secondary growths at distant sites.

References

1. Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors. Molecular Cancer (2023).
2. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. International Journal of Molecular Sciences (2020).
3. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors (2018).
4. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Frontiers in Oncology (2019).
5. Structure and Function of Human Matrix Metalloproteinases. Cells (2020).
6. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. BMC Cancer (2019).
7. Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. PLOS ONE (2015).